Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
iTeos Therapeutics
Biotech
iTeos drops one of 3 clinical assets from pipeline
iTeos is deprioritizing a phase 2 NSCLC asset after it failed to meet the biotech's bar for further investment.
Gabrielle Masson
Dec 12, 2024 3:10pm
ESMO: iTeos-GSK's TIGIT star shows meaningful improvement
Sep 14, 2024 2:30am
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
GSK on anti-TIGIT strategy: It’s 'not always about being first'
Sep 9, 2022 10:40am
Roche's trial flop casts shadow on Big Pharma's $6B TIGIT bet
May 16, 2022 9:45am
Roche's TIGIT flop prompts GSK to evaluate next steps for rival
May 13, 2022 4:52am
